Acute Myeloblastic Leukaemia in a Patient with Downs Syndrome and Sickle Cell Anaemia: A Case Report

Chika Duru*,1, Crosdale Pughikumo2 and Oyedeji Adeyemi3

1Department of Paediatrics and Child Health, Niger Delta University Teaching Hospital, Okolobri, Bayelsa State, Nigeria
2Department of Haematology, Niger Delta University Teaching Hospital, Okolobri, Bayelsa State, Nigeria

Introduction

Downs syndrome (DS) is the most common postnatally viable chromosomal anomaly. It has an incidence of about 1 in 700 live births [1]. Certain malignancies occur more frequently in persons with Downs syndrome compared to others. They include leukaemias, gonadal and extragonadal germ cell tumours and retinoblastomas [2,3].

Children and adolescents with Downs Syndrome have a 10-30 fold increased incidence of leukaemia [1]. This suggests an important role for some chromosome 21 genes located in leukaemogenesis [2]. Notably, the AML 1 gene, a critical regulator of normal haematopoeisis located at 21q22 is involved in 25% of childhood acute lymphoblastic Leukaemia(ALL) and 15% of acute Myeloblastic Leukaemia (AML) [2,3].

The age of onset for leukaemia in Downs syndrome is bimodal, peaking first in the newborn period and again at 3-6 years. Congenital leukaemia also occurs with increased frequency in Downs syndrome and is characterized by a preponderance of AML as in non-Downs syndrome children [3-5].

AML in Downs syndrome almost exclusively presents before the age of 4 years and the commonest type is acute megakaryoblastic (AMkL) which is extremely rare in non-Downs syndrome children [1,3,5]. Recent reports indicate that Down syndrome children with AML especially AMkL have exceptionally high cure rates with event free survival (EFS) rates ranging from 80-100%. This is in contrast to EFS less than 35% for non-Downs syndrome children [6,7].

The sickle cell haemoglobin (HbS) is caused by a point mutation in the beta haemoglobin gene located on chromosome 11. Sickle cell disease (SCD) results from the inheritance from both parents of the sickle haemoglobin (HbS) or of HbS and another pathologic variant haemoglobin such as Haemoglobin C (HbS+C) and beta thalassemia (HbS+β-thalassemia) [8,9].

Sickle cell disease is the commonest genetic disorder and sickle cell anaemia (HbSS) is very frequently seen in Africa [9]. The incidence of SCD is about 48 per thousand live births in Africa [8,9]. In Nigeria, about 150,000 babies are born with sickle cell anaemia yearly [9]. There are several individual case reports documenting the occurrence of malignancy in patients with SCD worldwide [10-18]. A small series of collection of cases of malignancy in SCD have also been reported [19,20].

In an institutional study by Dawkins et al., [21] the cancer incidence in SCD was 1.74 per thousand years. Schultz and Ware 22 in a multi-institutional study found 52 cases of malignancy in 16,613 Sickle cell disease cases; fourteen patients had haematological malignancies, two of which were AML. Karyotypic analysis of some of the cases revealed alterations in chromosomes [5,7,17,21].

A few cases of SCD with AML have been reported [10,12,19,22]. While it is not improbable that the commonest chromosomal abnormality may coexist with the commonest genetic disorder, in reality it is extremely rare. In our literature search, only one case report of Downs syndrome and HbS/β-thalassemia was reported in Chicago [23].

The appearance of AML in a patient with coexistent Downs Syndrome and sickle cell disease was not seen in our literature search. We hereby present a case of this triple combination, probably the first reported in medical literature, highlighting the challenges in diagnosis and management.

Case Report

The patient KA presented to the paediatric department of the Niger Delta University Teaching Hospital Okolobri Bayelsa State in Nigeria at the age of 4 months. He presented with a history of visible abdominal movement and swelling and failure to thrive since birth, fever and cough of 1 day duration.

There was a positive history of delayed passage of meconium at birth. He is the fourth child of a 35 years old mother in a monogamous non-consanguineous union.

On presentation, the child was pale, febrile with dysmorphic features- flat occiput, webbed neck, flattened nasal bridge, low set ears, wide spaced nipples, simian crease, short digits, protruding tongue, wide space between the big toe and second digit and whitish specks in both eyes (Figure 1). He had a distended abdomen with visible peristaltic movement and tenderess on palpation with hepatomegaly and splenomegaly both of 6 cm below the right and left costal margins respectively. He was in respiratory distress with a respiratory rate of 44 cpn and a heart rate of 140 bpm with normal heart sounds and no murmur.

An assessment of possible Downs syndrome with Hirschprungs disease, Bronchopneumonia and bilateral congenital cataract was made. A complete blood count done on admission revealed a Packed Cell Volume (PCV) of 17.9%, Platelets count-74×10⁹/l, Total White cell count (WBC)-5.4×10⁹/l, WBC differential count: neutrophils-25% lymphocytes-66%, monocytes-6% eosinophils-3%. He was transfused with fresh whole blood and commenced on intravenous broad spectrum antibiotics.

Following review by the haematologist, a peripheral blood film was done which showed moderate anisopoikilocytosis, polychromasia,
target cells and occasional sickle cells. There was relative lymphocytosis with some poorly characterised large cells? Blasts (Figure 2). An impression of Down syndrome with Sickle Cell disease was made to rule out Acute leukaemia. Requests were made for haemoglobin electrophoresis, bone marrow aspiration (BMA) and serum electrolytes, urea, creatinine and uric acid.

Haemoglobin electrophoresis done on admission and repeated later at 18 months of age confirmed HbSS. Serum potassium and sodium were normal while the Urea 2.0 mmol/l (2.4-6.0) and Creatinine 25 mmol/L (60-120) levels were low. Serum uric acid was elevated 520 μmol/L (120-420). Bone marrow aspiration revealed depressed erythropoiesis, myeloid hyperplasia with myeloblasts constituting about 70% of marrow nucleated cells. The myeloblasts were granulated with occasional Auer rods. Myeloid maturation arrest was also noted (Figures 3 and 4). An impression of acute myeloblastic leukaemia AML-M2 by morphology was made. There are no facilities in our institution for immunocytochemistry and karyotyping so we could not undertake immunologic classification and cytogenetic studies.

The parents were counselled on the nature of the child’s disease, management options and prognosis and the child was subsequently worked up for chemotherapy. Electrocardiogram done pre chemotherapy was normal. The patient’s age, background sickle cell disease, other associations like Hirschsprung’s disease, susceptibility to infections and our low capacity for supportive care were major impediments to aggressive chemotherapy. So we instituted chemotherapy with the traditional regimen of Daunorubicin and Cytosine Arabinoside at slightly sub-optimal doses. This was preceded by intravenous hydration and oral allopurinol for 24 hours.

A repeat BMA after 21 days was done showed only partial remission by morphology, so a re-induction was undertaken using the same drugs at full doses. This was backed by haematological support and surveillance of treatment of infections which were quite frequent. Another BMA done after 21 days following this re-induction showed complete remission by morphology (Figures 5 and 6). Repeat serum electrolytes, urea, creatinine and uric acid showed normal values.

The patient then underwent consolidation therapy with the same drugs over the next four months. He showed remarkable response with appreciable weight gain. He was transfused with whole blood six times during the course of his treatment and also treated for recurrent cutaneous and respiratory infections.

Presently, our patient is twenty months old and clinically stable following completion of chemotherapy. He is on routine haematinics and antimalarial preventive therapy and is presently being followed up.
in our outpatient paediatric haematology clinic and being evaluated for the other complications like Hirshprungs disease and bilateral congenital cataracts.

Discussion

The association between Down’s syndrome (DS) and malignancy has been established for over 90 years, [1-7] but no definite relationship between Sickle cell disease (SCD) and malignancy [17-19]. Only one report of DS coexisting with SCD was seen in our literature search [23].

Our patient has Down’s syndrome, SCD and AML-M2 by morphology using the French- American- British (FAB) classification. AML-M2 is associated with the translocation t (8,21) [24]. The presence of an extra chromosome 21 probably increases the chance of having this translocation. We could not rule out other chromosomal abnormalities in this patient because there are no facilities for karyotyping.

A major diagnostic challenge in DS patients with acute leukemia is posed by the presence of transient myeloproliferative disorder (TMD), also called transient leukaemia. It occurs in about 10% of DS patients [2]. TMD is usually recognised by the presence of megakaryoblasts in the peripheral blood, liver and bone marrow. Typically, most cases present at birth or shortly after and remit by three months, though a few cases persist beyond this [2,25,26]. After spontaneous remission of TMD, 10-30% of cases develop AML after 1-30 months [25,26]. Our patient was diagnosed at the age of 4 months, had no megakaryoblasts in the peripheral blood and the bone marrow blasts had obvious granulocytic maturation.

Knowing the rapidly fatal nature of AML 24 but mindful of the complications, we commenced chemotherapy cautiously. We were also encouraged by the reports of favourable outcome in Japanese DS children with AML occurring before the age of two years having a better prognosis. Taga et al. [30] also reported a poor outcome in Japanese DS children with AML occurring above the age of four years. This case highlights the challenges in the diagnosis and management of DS children with SCD complicated by AML, but the treatment can be quite rewarding even in resource-poor settings.

References

1. Rajani J (1996) Leukaemia in Down syndrome. The Cancer Journal 9: 151-154.
2. Dixon N, Kishnani PS, Zimmerman S (2006) Clinical manifestations of hematologic and oncologic disorders in patients with Down syndrome. Am J Med Genet C Semin Med Genet 142C: 149-157.
3. Xavier AC, Ge Y, Taub JW (2009) Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beamount hospital symposium on molecular pathology. J Mol Diagn 11: 371-380.
4. Fong CT, Brodeur GM (1987) Down’s syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis. Cancer Genet Cytogenet 28: 55-76.
5. Ravindranath Y (2005) Down syndrome and leukemia: new insights into the epidemiology, pathogenesis, and treatment. Pediatr Blood Cancer 44: 1-7.
6. Xavier AC, Taub JW (2010) Acute leukemia in children with Down syndrome. Haematologica 95: 1043-1045.
7. Zeller B, Gustafsson G, Forestier E, Abrahamsson J, Clausen N, et al. (2005) Acute leukemia in children with Down syndrome: a population-based Nordic study. Br J Haematol 128: 797-804.
8. Finkin F, Chesterman C, Penington D, Rush B, De Gruchy (2005). Clinical Haematology in Medical Practice. Blackwell Science, Oxford. 5th Edition 2005: 137-171.
9. Akinyanju O (2006) Control of sickle cell disease in Africa. Nigerian Journal of Clinical and biochemical research 1: 26-32.
10. Goldin AG, Kelty KC, Beard MF (1953) Sickle cell anemia terminating in acute myeloblastic leukemia. Ann Intern Med 93: 920-928.
11. Anderson IS, Yeung KY, Hillman D, Lessin LS (1975) Multiple myeloma in a patient with sickel cell anemia. Interacting effects on blood viscosity. Am J Med 59: 568-574.
12. Samal GC (1979) Sickle cell anemia with acute myeloid leukemia—a case report. Indian Pediatr 16: 453-454.
13. Salmassi S, Currie ET, Bolf EC, Hernandez M, Kasprisin DO (1981) Management of Hodgkin’s disease in a patient with sickle cell anemia. Cancer 48: 252-254.
14. Morabito F, Callea V, Brugiatelli M, D’Ascola D, Palazzolo A, et al. (1987) Non-Hodgkin’s lymphoma associated with sickle cell disease: a case report. Tumori 73: 523-524.
15. Labi M, Haponik EF, Welsh RA, Summer WR (1989) Alveolar cell carcinoma complicating sickle cell anemia: a chance occurrence? Am J Hematol 32: 222-225.
16. Shokunbi WA, Campbell OB, Ogunbiyi JO (1996) Malignant haemangiendothelioma of bone in a HSSC disease patient—a case report. Afr J Med Sci 25: 292-296.
17. Brown BJ, Kottila TR (2007) Hodgkin lymphoma in a child with sickle cell anemia. Pediatr Hematol Oncol 24: 531-535.
18. Olatunji PO, Olatunji AA, Shonde-Adebolu AS (2012) Lymphoplasmacytoid Lymphoma with Polyclonal Gammopathy in a patient with sickle cell anaemia. Annals of Tropical Pathology 3: 62-70.
19. Sticker RB, Linker CA, Crowley TJ, Embury SH (1986) Hematologic malignancy in sickle cell disease: report of four cases and review of the literature. Am J Hematol 21: 223-230.
20. Baron BW, Mick R, Baron JM (1994) Hematuria in sickle cell anemia—not always benign: evidence for excess frequency of sickle cell anemia in African Americans with renal cell carcinoma. Acta Haematol 92: 119-122.

Figure 6: Bone marrow aspirate showing complete remission (high power).
21. Baz W, Najfeld V, Yotsuya M, Talwar J, Terjian T, et al. (2012) Development of myelodysplastic syndrome and acute myeloid leukemia 15 years after hydroxyurea use in a patient with sickle cell anemia. Clin Med Insights Oncol 6: 149-152.

22. Schultz WH, Ware RE (2003) Malignancy in patients with sickle cell disease. Am J Hematol 74: 249-253.

23. Melnyk AR, Adams BW, Suarez CR (1990) Down syndrome complicated by hemoglobin S/beta+ thalassemia. Atypical expression of coexistent disease. Clin Pediatr (Philad) 29: 331-335.

24. Bain BJ (2005) Diagnosis and classification of Acute Leukaemia. In: Postgraduate Haematology. Eds: Hoffbrand AV, Catovsky D, Tuddenham EDG. Blackwell Publishing, Oxford: 476-491.

25. Homans AC, Verissimo AM, Vlacha V (1993) Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol 15: 392-399.

26. Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, et al. (2006) A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS). Children’s Oncology Group (COG) study POG-9481. Blood 107: 4606-4613.

27. Paydas S (2002) Sickle cell anemia and hematological neoplasias. Leuk Lymphoma 43: 1431-1434.

28. Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, et al. (1992) Acute myeloid leukemia (AML) in Down’s syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 80: 2210-2214.

29. Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, et al. (2003) Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children’s Cancer Group Study 2891. J Clin Oncol 21: 3415-3422.

30. Taga T, Shimomura Y, Horikoshi Y, Ogawa A, Itoh M, et al. (2011) Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children’s cancer and leukemia study group (JCCLSG) AML 9805 down study. Pediatr Blood Cancer 57: 36-40.